Skip to main navigation Skip to search Skip to main content

Hepatic Artery Infusion Chemotherapy Compared to Transarterial Radioembolization for Unresectable Colorectal Liver Metastases

  • Lily V. Saadat
  • , Joanne Chou
  • , Mithat Gonen
  • , Rachel M. Lee
  • , Shishir K. Maithel
  • , Amy Li
  • , George A. Poultsides
  • , Taylor J. Aiken
  • , Patrick B. Schwartz
  • , Ece Meram
  • , Daniel E. Abbott
  • , Keenan J. Robbins
  • , Ryan C. Fields
  • , Ashwini Paranjpe
  • , Jashodeep Datta
  • , Louise C. Connell
  • , Leonard Saltz
  • , Andrea Cercek
  • , Nancy Kemeny
  • , Daniel Y. Sze
  • Hooman Yarmohammadi, Constantinos T. Sofocleous, William Jarnagin, Michael D’Angelica

Research output: Contribution to journal › Article › peer-review

Abstract

Objective: This study evaluates outcomes for patients with unresectable colorectal liver metastases (CRLM) undergoing hepatic artery infusion chemotherapy (HAI) and transarterial radioembolization (TARE). Summary Background Data: The most common liver-directed therapies for unresectable CRLM include HAI and TARE. Methods: In this retrospective cohort study, patients with unresectable CRLM treated with HAI at one high-volume center were compared with patients treated with TARE at five other institutions. Propensity score matching was performed within lines of chemotherapy received prior to treatment (treatment-naïve; 1-line; 2-lines; 3-4 lines) using baseline demographics, extrahepatic disease (EHD), prior chemotherapy, disease-free interval, and interval from primary diagnosis to HAI/TARE. Overall survival (OS) analysis was conducted to compare the matched groups. Results: A total of 708 HAI patients and 481 TARE patients were identified. The majority of patients (84%) received chemotherapy prior to HAI/TARE. HAI patients were younger (median age:54 vs. 62) and more likely to have evidence of EHD at time of treatment (65% vs. 60%). Of the 493 patients who received 1-line of chemotherapy, 166 (34%) were matched. Among matched patients who received 1-line (HAI:83, TARE:83) or 2-lines of chemotherapy (HAI:80, TARE:80), TARE patients had a significantly increased risk of all-cause mortality compared to HAI [HR:1.46 (95%CI:1.02-2.08) and HR:1.96 (95%CI:1.32-2.89)]. More frequent conversion to resection and use of concurrent systemic chemotherapy were also seen in the HAI cohort. Among matched patients who received 3-4 lines of chemotherapy (HAI:50, TARE:50), there was no difference in OS between HAI and TARE [HR:0.88 (95%CI:0.57-1.35)] and rate of conversion to surgery was 4% for both groups. Conclusions: Within matched cohorts stratified by lines of therapy, there appear to be differences in survival for patients treated with HAI and TARE after first or second-line chemotherapy. Outcomes after TARE and HAI are not significantly different in the refractory setting.

Original languageEnglish (US)
Article number10.1097/SLA.0000000000006851
JournalAnnals of surgery
DOIs
StateAccepted/In press - 2025
Externally publishedYes

Bibliographical note

Publisher Copyright:
Copyright © 2025 Wolters Kluwer Health, Inc.

Keywords

  • Colorectal Liver Metastases
  • HAI
  • TARE

PubMed: MeSH publication types

  • Journal Article

Fingerprint

Dive into the research topics of 'Hepatic Artery Infusion Chemotherapy Compared to Transarterial Radioembolization for Unresectable Colorectal Liver Metastases'. Together they form a unique fingerprint.

Cite this